Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Beyond Hematopoietic Property; Administration of Erythropoietin for Nephroprotection Publisher



Bahadorimonfared A1 ; Alirezaei A2 ; Zare E3 ; Bakhtiyari M4, 5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Health and Community Medicine, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  2. 2. Clinical Research and Development Center at Shahid Modarres Hospital, Department of Nephrology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  3. 3. Department of Internal Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  4. 4. Department of Community Medicine, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran
  5. 5. Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

Source: Journal of Renal Injury Prevention Published:2017


Abstract

Acute kidney injury (AKI) is defined as an abrupt or rapid decline in renal filtration function. Erythropoietin (EPO) as a hematopoietic and multifunctional hormone is produced primarily by kidney. Many investigations have shown that EPO as an antioxidant agent has shown several effects such as anti-apoptotic, antioxidant, and anti-inflammatory and also angiogenic activities. The biological activities of EPO are mediated by binding to its receptor (EPOR). The potential role of EPO in kidney is related to the presence of functional EPOR in renal mesangial cells, tubular epithelial cells and the glomerulus. Antioxidants and reactive oxygen species (ROS) scavengers such as EPO, can protect the kidneys against conditions that induce nephrotoxicity. Most studies in the field of renoprotective effects of EPO have focused on AKI models. In this paper we sought to review the ameliorative effects of EPO against various agents or conditions that induce nephrotoxicity including ischemia/reperfusion injury (IRI), cisplatin, gentamicin, rhabdomyolysis, amikacin and vancomycin. © 2017 The Author(s).
Related Docs
1. Identification of Methionine Oxidation in Human Recombinant Erythropoietin by Mass Spectrometry: Comparative Isoform Distribution and Biological Activity Analysis, Preparative Biochemistry and Biotechnology (2017)
Experts (# of related papers)
Mohammad Reza Khorramizadeh (1)
Mahdi Aminian (1)